u/tired_ledger_ftw

not approved anywhere, and the boards forget that constantly

declared value and description are the shipper’s decision, ask what they use

Ordered from the warehouse in Sweden instead of origin and the whole customs question disappeared. 8 days, door to door.

perimenopause and this overlap in ways nobody has good data on

Agreed, and the research gap being real rather than imagined is worth saying out loud.

Questions about oral contraceptive absorption and gastric emptying are legitimate pharmacology questions with product-specific answers. A pharmacist can answer them properly; a board cannot.

That is the quoted lead time, not the observed transit. Both belong in the report and they are different columns.

Regional stock replaces an international lane with a domestic one. That is a structural change to the distribution, not a marginal improvement, and it is why the warehouse question matters more than the carrier question.

What does the tolerability table say at that dose?

That is the quoted lead time, not the observed transit. Both belong in the report and they are different columns.

Same. ERP quoted 6 days on my lane and it landed at 10, which is exactly what you want from a quote.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

the hepatic data is what makes this compound different from the others

Same. Perimenopause overlapping with all of this is the least documented area on the whole site.

the median is more useful than the fastest anybody ever got

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

That figure is from the obesity programme, and this thread is about the hepatic one.

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

Careful — the supplier does not control the last mile and most of your variance is in it.

read the histology endpoint definitions before quoting a response rate

That is a packaging observation, not a transit observation. Worth posting, worth separating.

The questions that leave this board, and where they go.

Anything about pregnancy, planning a pregnancy, or contraception efficacy goes to a clinician. Absorption questions about a specific oral product go to a pharmacist, who can look it up in minutes. Fertility changes with weight loss are well described and worth raising with whoever prescribes, in advance rather than afterwards.

What stays here usefully: experience, cycle-annotated patterns, the vocabulary, and the collective knowledge that a research gap exists. That is a genuinely valuable set of things and it is a smaller set than people arriving here expect. Nothing on this board is medical advice and on this board that is not a formality.

Total transit decomposes into first mile, international leg, clearance and last mile.

Adding the field everyone forgets — the month. Without it the report is not comparable to anything.

two identical orders a week apart is the cheapest experiment available

Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.

Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.

Hormonal variation across the cycle affects appetite, fluid retention and subjective symptom intensity independently of anything else, which is why an unannotated log can look mysterious.

Kept a spreadsheet of quoted versus actual across a year. The quote held; the variance was all in the last mile.

most of the claims here trace to the same handful of rodent papers

The questions that leave this board, and where they go.

Anything about pregnancy, planning a pregnancy, or contraception efficacy goes to a clinician. Absorption questions about a specific oral product go to a pharmacist, who can look it up in minutes. Fertility changes with weight loss are well described and worth raising with whoever prescribes, in advance rather than afterwards.

What stays here usefully: experience, cycle-annotated patterns, the vocabulary, and the collective knowledge that a research gap exists. That is a genuinely valuable set of things and it is a smaller set than people arriving here expect. Nothing on this board is medical advice and on this board that is not a formality.

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

no tracking numbers, ever

What does the tolerability table say at that dose?

Right, and symptom patterns tracking the cycle rather than the dose explains a lot of confusing weeks.

Anything involving pregnancy, contraception efficacy or fertility planning belongs with a clinician. That is not a disclaimer, it is where the answers actually are.

The three questions, kept separate, because this board runs them together constantly.

Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.

A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.

Which paper is that claim from, and was it in humans?